Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:33:50.948Z.
Calculation as of: 2026-10-06T17:33:50.948Z.
Quote observation: 2026-10-06T17:30:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e64ee45e162b8fcb3c04564696a4f5631675aa9d571ebc51c9b2157b48bafcf8
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $51.60M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $51.79M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.95M | N/A | 135.17 | 135.17 | 135.17 |
| biote Corp. (BTMD)vs › | $53.37M | 10.37 | 4.82 | 27.98 | 18.54 |
| Tenax Therapeutics, Inc. (TENX)vs › | $50.66M | N/A | 1.95 | 1.95 | 1.95 |
| Clene Inc. (CLNN)vs › | $50.67M | N/A | 13.56 | 13.56 | 13.56 |
| Aldeyra The (ALDX)vs › | $52.87M | N/A | 2.27 | 2.27 | 2.27 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $49.64M | N/A | 11.46 | 11.53 | 11.53 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.79
Forward EPS (Est.)
$-0.17
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
